Chinese study shows some Omicron sub-variants escaping antibodies from Sinopharm COVID vaccine
Neutralising activity against those sub-variants was observed in just 24-48% of subjects who received a BBIBP-CorV booster shot after the two-dose product, researchers said, citing results from a group of 25 participants.
Beijing: A small Chinese study detailed in The Lancet Infectious Diseases journal showed neutralising antibodies against some Omicron sub-variants were largely undetectable after two doses of a Sinopharm COVID-19 vaccine, with a booster shot only partly restoring them.
The study comes as China, which has approved only locally developed COVID shots including the Sinopharm vaccine, strives to improve vaccination rates, maintaining a "dynamic zero COVID" policy aimed at eradicate all outbreaks while many countries have adopted an approach of learning to live with the virus.
The vaccine, BBIBP-CorV, is one of the two Sinopharm COVID shots approved for use in China, and is also the main shot that the state-owned firm has exported.
Read also: Experts disapprove using Chinese vaccine Sinopharm on Sri Lankans: Report
Among 25 individuals who received two doses of BBIBP-CorV vaccine, the neutralising activity against sub-variants such as BA.2.12.1 and BA.4/BA.5 "was not or only minimally detectable", researchers said in correspondence published on Monday.
Neutralising activity against those sub-variants was observed in just 24-48% of subjects who received a BBIBP-CorV booster shot after the two-dose product, researchers said, citing results from a group of 25 participants.
Read also: WHO nod to Sinopharm Covid-19 vaccine for emergency use
The rate improved slightly, to 30-53%, for those who received a third shot made by a unit of Chongqing Zhifei Biological Products, another vaccine approved for use in China, according to data from another group of 30 subjects.
The study did not discuss the boosters' efficacy, a rate that reflects how well they could lower the risk of COVID disease or death, which is usually observed in large clinical trials.
Read also: Sinovac, Sinopharm Omicron-specific vaccine candidates approved for clinical trial in Hong Kong
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd